Journal
CLINICAL CANCER RESEARCH
Volume 25, Issue 23, Pages 6887-6889Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-19-2585
Keywords
-
Categories
Funding
- U.T. MD Anderson Cancer Center
- U.S. Department of Defense (DOD) [CA160445]
Ask authors/readers for more resources
Microsatellite instable tumors often respond to immune checkpoint blockade (ICB), however, tumor tissue is unavailable/insufficient in some patients. Two groups are reporting a blood-based assessment of the microsatellite status validated in tumor tissue and by clinical benefit in patient receiving ICB. Both approaches are highly appealing with a few caveats.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
